PH12017500224B1 - Method for enhancing immune cell function and method for assessing immune cell multifunctionality - Google Patents
Method for enhancing immune cell function and method for assessing immune cell multifunctionalityInfo
- Publication number
- PH12017500224B1 PH12017500224B1 PH12017500224A PH12017500224A PH12017500224B1 PH 12017500224 B1 PH12017500224 B1 PH 12017500224B1 PH 12017500224 A PH12017500224 A PH 12017500224A PH 12017500224 A PH12017500224 A PH 12017500224A PH 12017500224 B1 PH12017500224 B1 PH 12017500224B1
- Authority
- PH
- Philippines
- Prior art keywords
- multifunctionality
- immune
- immune cell
- immune cells
- antidiabetic drug
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 10
- 230000002708 enhancing effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000003915 cell function Effects 0.000 title abstract 2
- 229940123208 Biguanide Drugs 0.000 abstract 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 abstract 4
- 229940127003 anti-diabetic drug Drugs 0.000 abstract 4
- 239000003472 antidiabetic agent Substances 0.000 abstract 4
- 229960004111 buformin Drugs 0.000 abstract 3
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 abstract 3
- 229960003105 metformin Drugs 0.000 abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 3
- 229960003243 phenformin Drugs 0.000 abstract 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001965 increasing effect Effects 0.000 abstract 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014166593 | 2014-08-19 | ||
JP2015085556 | 2015-04-20 | ||
PCT/JP2015/073011 WO2016027764A1 (ja) | 2014-08-19 | 2015-08-17 | 免疫細胞の機能増強方法及び免疫細胞の多機能性評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12017500224B1 true PH12017500224B1 (en) | 2017-07-10 |
PH12017500224A1 PH12017500224A1 (en) | 2017-07-10 |
Family
ID=55350709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12017500224A PH12017500224A1 (en) | 2014-08-19 | 2017-02-07 | Method for enhancing immune cell function and method for assessing immune cell multifunctionality |
Country Status (15)
Country | Link |
---|---|
US (2) | US20170231929A1 (de) |
EP (2) | EP3232199B1 (de) |
JP (3) | JP6629211B2 (de) |
KR (1) | KR20170042778A (de) |
CN (1) | CN107148274A (de) |
AU (1) | AU2015304448B2 (de) |
BR (1) | BR112017002807A2 (de) |
CA (1) | CA2958573A1 (de) |
ES (1) | ES2915849T3 (de) |
IL (1) | IL250639B (de) |
MX (1) | MX2017002134A (de) |
PH (1) | PH12017500224A1 (de) |
RU (2) | RU2731098C2 (de) |
SG (2) | SG10202005315SA (de) |
WO (1) | WO2016027764A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121168A1 (en) * | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
PT3081576T (pt) | 2013-12-12 | 2019-10-15 | Jiangsu Hengrui Medicine Co | Anticorpo pd-1, fragmento de ligação ao antigénio do mesmo e aplicação médica do mesmo |
CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
CN107082812B (zh) | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
BR112019025478A8 (pt) * | 2017-06-02 | 2022-12-06 | Bayer Ag | Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer |
WO2019069449A1 (ja) * | 2017-10-06 | 2019-04-11 | 純児 赤木 | 測定方法 |
WO2019124423A1 (ja) * | 2017-12-19 | 2019-06-27 | 国立大学法人 岡山大学 | がんの進行抑制、治療、予防及び/又は再発予防剤 |
JP2019112353A (ja) * | 2017-12-25 | 2019-07-11 | 合同会社チューモス | 自家腫瘍ワクチン及び免疫誘導方法 |
US11959916B2 (en) * | 2017-12-26 | 2024-04-16 | Tamio Yamauchi | Method, system, and program for supplying immunodynamics-related information |
KR102338992B1 (ko) * | 2018-01-05 | 2021-12-14 | 지엔티 바이오테크 & 메디컬즈 코포레이션 | 종양 미세환경 및 면역요법의 조절을 위한 약제학적 조합물 및 방법 |
WO2019202473A1 (en) * | 2018-04-16 | 2019-10-24 | Université de Lausanne | Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade |
US20220017969A1 (en) * | 2018-12-07 | 2022-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members |
KR102510381B1 (ko) * | 2019-10-16 | 2023-03-15 | 한국과학기술원 | 메트포민을 유효성분으로 포함하는 뇌암의 예방 또는 치료용 면역치료제 조성물 |
WO2022072745A1 (en) * | 2020-10-01 | 2022-04-07 | The Regents Of The University Of California | Methods and compositions to treat and prevent viral infections and acute respiratory distress syndrome |
CN112791182A (zh) * | 2020-12-31 | 2021-05-14 | 中山大学 | 二甲双胍和抗pd-1抗体药物组合物在制备肝癌药物中的应用 |
CN113421627B (zh) * | 2021-05-11 | 2023-04-07 | 深圳市罗湖区人民医院 | 体外评估药物对nk细胞抗衰作用的系统 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US5260275A (en) * | 1990-08-14 | 1993-11-09 | Amylin Pharmaceuticals, Inc. | Hypoglycemics |
AU705114B2 (en) * | 1993-10-14 | 1999-05-13 | Immunex Corporation | Fas antagonists and uses thereof |
AU2001276598A1 (en) * | 2000-08-07 | 2002-02-18 | Ranbaxy Signature Llc | Liquid formulation of metformin |
EP2206517B1 (de) * | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
WO2006121168A1 (en) | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
WO2009030257A1 (en) * | 2007-09-05 | 2009-03-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Methods and compounds for treating diseases caused by reactive oxygen species |
CN102596192A (zh) * | 2009-08-25 | 2012-07-18 | 哈佛大学校长及研究员协会 | 二甲双胍在癌症治疗和预防中的用途 |
US20130059916A1 (en) * | 2010-05-26 | 2013-03-07 | Stephane Rocchi | Biguanide compounds and its use for treating cancer |
MX2013007835A (es) * | 2011-01-11 | 2014-04-14 | Univ Basel | Combinacion de sirosingopina e inhibidores mitocondriales para el tratamiento de cancer e inmunosupresion. |
WO2013009535A1 (en) * | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
CN103371991A (zh) * | 2012-04-18 | 2013-10-30 | 中国人民解放军第二军医大学 | 二甲双胍在制备预防或治疗肝细胞癌药物中的应用 |
DK2872646T3 (en) * | 2012-07-12 | 2017-12-04 | Université Paris Descartes | PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES |
LT2880180T (lt) * | 2012-08-06 | 2019-01-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai |
PT2904011T (pt) * | 2012-10-02 | 2017-10-27 | Bristol Myers Squibb Co | Combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar cancro |
WO2014083095A1 (en) * | 2012-11-29 | 2014-06-05 | Universitaet Basel | Combinations of metformin with other compounds for the treatment of cancer and for immunosuppression |
TWI664976B (zh) * | 2013-01-02 | 2019-07-11 | 美商迪科生物系統公司 | 使用細菌治療癌症之組成物和方法 |
JP6242071B2 (ja) * | 2013-04-23 | 2017-12-06 | 国立大学法人 岡山大学 | 免疫疲弊cd8+t細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬 |
-
2015
- 2015-08-17 WO PCT/JP2015/073011 patent/WO2016027764A1/ja active Application Filing
- 2015-08-17 BR BR112017002807A patent/BR112017002807A2/pt not_active IP Right Cessation
- 2015-08-17 EP EP17174222.4A patent/EP3232199B1/de active Active
- 2015-08-17 EP EP15833898.8A patent/EP3192517A4/de not_active Withdrawn
- 2015-08-17 SG SG10202005315SA patent/SG10202005315SA/en unknown
- 2015-08-17 CA CA2958573A patent/CA2958573A1/en not_active Abandoned
- 2015-08-17 JP JP2016544195A patent/JP6629211B2/ja active Active
- 2015-08-17 CN CN201580043408.XA patent/CN107148274A/zh active Pending
- 2015-08-17 SG SG11201700978SA patent/SG11201700978SA/en unknown
- 2015-08-17 KR KR1020177007514A patent/KR20170042778A/ko not_active Application Discontinuation
- 2015-08-17 RU RU2017108754A patent/RU2731098C2/ru active
- 2015-08-17 RU RU2020127099A patent/RU2020127099A/ru unknown
- 2015-08-17 ES ES17174222T patent/ES2915849T3/es active Active
- 2015-08-17 US US15/503,247 patent/US20170231929A1/en not_active Abandoned
- 2015-08-17 AU AU2015304448A patent/AU2015304448B2/en not_active Ceased
- 2015-08-17 MX MX2017002134A patent/MX2017002134A/es unknown
-
2017
- 2017-02-07 PH PH12017500224A patent/PH12017500224A1/en unknown
- 2017-02-16 IL IL250639A patent/IL250639B/en active IP Right Grant
- 2017-04-20 JP JP2017083767A patent/JP6672217B2/ja active Active
- 2017-06-20 US US15/628,600 patent/US20170281569A1/en not_active Abandoned
-
2020
- 2020-03-03 JP JP2020035992A patent/JP2020109098A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6629211B2 (ja) | 2020-01-15 |
EP3232199A3 (de) | 2018-02-14 |
BR112017002807A2 (pt) | 2017-12-19 |
PH12017500224A1 (en) | 2017-07-10 |
EP3192517A1 (de) | 2017-07-19 |
AU2015304448B2 (en) | 2020-04-30 |
CA2958573A1 (en) | 2016-02-25 |
RU2731098C2 (ru) | 2020-08-28 |
JP2017165752A (ja) | 2017-09-21 |
SG10202005315SA (en) | 2020-07-29 |
EP3232199A8 (de) | 2017-12-13 |
US20170281569A1 (en) | 2017-10-05 |
EP3232199B1 (de) | 2022-05-04 |
IL250639A0 (en) | 2017-04-30 |
EP3232199A2 (de) | 2017-10-18 |
EP3192517A4 (de) | 2018-04-25 |
ES2915849T3 (es) | 2022-06-27 |
AU2015304448A1 (en) | 2017-03-09 |
RU2017108754A (ru) | 2018-09-20 |
JP6672217B2 (ja) | 2020-03-25 |
WO2016027764A1 (ja) | 2016-02-25 |
US20170231929A1 (en) | 2017-08-17 |
RU2017108754A3 (de) | 2019-03-29 |
JPWO2016027764A1 (ja) | 2017-06-01 |
SG11201700978SA (en) | 2017-03-30 |
MX2017002134A (es) | 2017-09-13 |
RU2020127099A (ru) | 2020-09-02 |
KR20170042778A (ko) | 2017-04-19 |
JP2020109098A (ja) | 2020-07-16 |
IL250639B (en) | 2020-02-27 |
CN107148274A (zh) | 2017-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500224B1 (en) | Method for enhancing immune cell function and method for assessing immune cell multifunctionality | |
MA39717A (fr) | Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs | |
PL3212208T3 (pl) | Zastosowanie bakterii l. reuteri do zapobiegania lub leczenia dysbiozy mikrobioty we wczesnych fazach życia | |
PH12016501978A1 (en) | Treatment of nafld and nash | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
PH12019550027A1 (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
WO2015110923A3 (en) | Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia | |
MA40620A (fr) | Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression | |
WO2015153857A8 (en) | Methods for enhancing the efficacy of a tumor-directed immune response | |
MX2020002070A (es) | Receptores solubles de interferon y usos de los mismos. | |
AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
SG10201901910YA (en) | Inject insert for epi chamber | |
MX2017005249A (es) | Compuestos para usarse en el tratamiento antihelmintico. | |
AU2016282877A8 (en) | Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias | |
MX2017008055A (es) | Vacunacion. | |
PH12019500496A1 (en) | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy | |
BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
EP4342544A3 (de) | Erhöhung der therapeutischen aktivität eines immun-checkpoint-inhibitors | |
HK1251449A1 (zh) | 用於治療2型糖尿病的交聯聚二烯丙基胺共聚物 | |
AR094873A1 (es) | Métodos y composiciones para detectar y tratar mutantes de akt resistentes a fármacos | |
BR112018003430A2 (pt) | uso de um copolímero de associação hidrofóbica, e, composição para pelotização de minério contendo metal | |
MX2017003556A (es) | Formas de dosificacion de fenilefrina de liberacion pulsada. | |
MX2017012231A (es) | Secuencias de oligonucleotidos dirigidos al factor de transcripcion tsc22d4 para el tratamiento de la resistencia a la insulina. |